

# CRAVATH, SWAINE & MOORE LLP

JOHN W. WHITE  
 EVAN R. CHESLER  
 PHILIP A. GELSTON  
 RICHARD W. CLARY  
 JAMES D. COOPER  
 STEPHEN L. GORDON  
 DANIEL L. MOSLEY  
 ROBERT H. BARON  
 DAVID MERCADO  
 CHRISTINE A. VARNEY  
 PETER T. BARBUR  
 SANDRA C. GOLDSTEIN  
 THOMAS G. RAFFERTY  
 MICHAEL S. GOLDMAN  
 RICHARD HALL  
 JULIE A. NORTH  
 ANDREW W. NEEDHAM  
 STEPHEN L. BURNS  
 KEITH R. HUMMEL  
 DAVID J. KAPPAS  
 DANIEL SLIFKIN  
 ROBERT I. TOWNSEND, III  
 WILLIAM J. WHELAN, III

PHILIP J. BOECKMAN  
 WILLIAM V. FOGG  
 FAIZA J. SAEED  
 RICHARD J. STARK  
 THOMAS E. DUNN  
 MARK I. GREENE  
 DAVID R. MARRIOTT  
 MICHAEL A. PASKIN  
 ANDREW J. PITTS  
 MICHAEL T. REYNOLDS  
 ANTHONY L. RYAN  
 GEORGE E. ZOBITZ  
 GEORGE A. STEPHANAKIS  
 DARIN P. MCATEE  
 GARY A. BORNSTEIN  
 TIMOTHY G. CAMERON  
 KARIN A. DEMASI  
 LIZABETHANN R. EISEN  
 DAVID S. FINKELSTEIN  
 DAVID GREENWALD  
 RACHEL G. SKAISTIS  
 PAUL H. ZUMBRO  
 JOEL F. HEROLD

**WORLDWIDE PLAZA**  
**825 EIGHTH AVENUE**  
**NEW YORK, NY 10019-7475**

TELEPHONE: +1-212-474-1000  
 FACSIMILE: +1-212-474-3700

CITYPOINT  
 ONE ROPEMAKER STREET  
 LONDON EC2Y 9HR  
 TELEPHONE: +44-20-7453-1000  
 FACSIMILE: +44-20-7860-1150  
 WRITER'S DIRECT DIAL NUMBER  
 +1-212-474-1430  
 WRITER'S EMAIL ADDRESS  
 dmarriott@cravath.com

ERIC W. HILFERS  
 GEORGE F. SCHOEN  
 ERIK R. TAIVEL  
 CRAIG F. ARCELLA  
 DAMIEN R. ZOUBEK  
 LAUREN ANGELILLI  
 TATIANA LAPUSHCHIK  
 ERIC L. SCHIELE  
 ALYSSA K. CAPLES  
 JENNIFER S. CONWAY  
 MINH VAN NGO  
 KEVIN J. ORSINI  
 MATTHEW MORREALE  
 JOHN D. BURETTA  
 J. WESLEY EARNHARDT  
 YONATAN EVEN  
 BENJAMIN GRUENSTEIN  
 JOSEPH D. ZAVAGLIA  
 STEPHEN M. KESSING  
 LAUREN A. MOSKOWITZ  
 DAVID J. PERKINS  
 JOHNNY G. SKUMPIJA  
 J. LEONARD TETI, II

D. SCOTT BENNETT  
 TINA S. CHEN  
 CHRISTOPHER K. FARGO  
 KENNETH C. HALCOM  
 DAVID M. STUART  
 AARON M. GRUBER  
 O. KEITH HALLAM, III  
 OMID H. NASAB  
 DAMARIS HERNÁNDEZ  
 JONATHAN J. KATZ  
 MARGARET SEGALL D'AMICO  
 RORY A. LERARIS  
 KARA L. MUNGUVAN

-----

SPECIAL COUNSEL  
 SAMUEL C. BUTLER  
 GEORGE J. GILLESPIE, III

-----

OF COUNSEL  
 MICHAEL L. SCHLER

May 18, 2017

Apotex, Inc. v. Cephalon, Inc. et al., No. 06-cv-2768 (MSG)  
Giant Eagle, Inc. v. Cephalon, Inc. et al., No. 10-cv-5164 (MSG)  
Walgreen Co. et al. v. Cephalon, Inc. et al., No. 09-cv-3956 (MSG)  
Rite Aid Corp. et al. v. Cephalon, Inc. et al., No. 09-cv-3820 (MSG)

Dear Judge Goldberg:

I write on behalf of Mylan Laboratories Inc. (now known as Mylan Inc.) ("Mylan Labs") to clarify an issue with the Court that has recently come to our attention.

As the Court is aware, Plaintiff Apotex is the only party with claims remaining against any Mylan entity. Apotex filed its initial Complaint on June 6, 2006; an Amended Complaint on August 10, 2009 (Doc. 149); and a Second Amended Complaint on January 6, 2010 (Doc. 195). All three complaints named only Mylan Labs as a defendant.

On April 29, 2010, Mylan Labs answered the Second Amended Complaint (Doc. 254). Mylan Labs opened by pointing out:

"As an initial matter, Mylan notes that, while Plaintiff has named Mylan as a defendant in this action, Mylan is not the holder of an ANDA for a generic version of Provigil® and is not a party to a settlement agreement with Cephalon resolving patent litigation related to that ANDA. Instead, Mylan's subsidiary, Mylan Pharmaceuticals, Inc. ("Mylan Pharmaceuticals") is the ANDA holder and settling party. Mylan therefore denies as stated any and all allegations in the Second Amended Complaint alleging or suggesting that Mylan is the ANDA holder for a generic version of Provigil® that Mylan is party to a settlement agreement with Cephalon, or that Mylan is a proper party to this action. By responding to the allegations in the Second Amended Complaint to the best of its knowledge, information and belief, Mylan does not waive and fully preserves its defense that it is not a proper party to this action." (Doc. 254 at 1-2.)

Apotex did not attempt to respond to Mylan Labs' objection. At no point in time between April 29, 2010 and this week did Apotex seek to add Mylan Pharmaceuticals as a party to its complaint. The direct purchaser plaintiffs, the end-payer plaintiffs and the retailer plaintiffs previously asserted claims against both Mylan Labs and/or Mylan Pharmaceuticals, but these claims have been settled.

On Tuesday of this week Apotex's counsel informed us that they are now, less than three weeks prior to trial, interested in amending their Second Amended Complaint to add Mylan Pharmaceuticals as a defendant. We have informed Apotex's counsel that we will not consent to such an amendment.

In the course of our conversation with counsel for Apotex, it came to our attention that certain pre-trial documents filed recently include references to both Mylan Labs and Mylan Pharmaceuticals. These references to Mylan Pharmaceuticals in the context of claims asserted by Apotex were inadvertently carried over from earlier filings submitted when Mylan Pharmaceuticals was, in fact, a defendant sued by other plaintiffs with which we have since settled.

Apotex has been on notice that it brought suit against the wrong party for over seven years, after being specifically advised that Mylan Labs did not hold the ANDA in question and was not a party to the settlement agreement with Cephalon. An amendment to add a claim against Mylan Pharmaceuticals would be untimely (indeed time-barred) and highly prejudicial as we are literally on the eve of trial. Apotex's change in strategy is an effort to upend our defense of the only remaining claims against our client. Apotex should not be permitted to amend its complaint at this late hour.

Respectfully submitted,



David R. Marriott

The Honorable Mitchell S. Goldberg  
United States District Court  
Eastern District of Pennsylvania  
601 Market Street, Room 7614  
Philadelphia, PA 19106

Copies to: All Counsel (via ECF)